Discovery of N-Aryl-Benzimidazolone Analogs as Novel Potential HSP90 Inhibitors: A Computational Approach

This study aims to identify N-aryl-benzimidazolone analogs as potential inhibitors of the HSP90 protein, which is involved in various diseases. For this, we used computational techniques such as pharmacophoric modeling, virtual screening, in silico ADMET prediction, and molecular dynamics simulations. A target-based pharmacophore model (ADDRR) was developed from the MEY ligand to identify the main binding features. This model was used to screen approximately 30,994 similar compounds, leading to the identification of 3019 candidates. Among these, five compounds (L1, L2, L3, L4, and L5) showed strong binding affinity, with docking scores lower than the reference ligand MEY (−7.94 kcal/mol). The ADMET properties of these compounds were favorable, confirming their potential as drug candidates. The two top-performing compounds in the docking studies demonstrated high stability in dynamics studies, the results demonstrated remarkable stability of the ligand−protein complexes, as evidenced by favorable values of metrics such as RMSD, RMSF, Rg, and SASA. These findings provide a promising foundation for further experimental validation and the potential development of effective HSP90 inhibitors.